Literature DB >> 16565718

Genetic clonal diversity predicts progression to esophageal adenocarcinoma.

Carlo C Maley1, Patricia C Galipeau, Jennifer C Finley, V Jon Wongsurawat, Xiaohong Li, Carissa A Sanchez, Thomas G Paulson, Patricia L Blount, Rosa-Ana Risques, Peter S Rabinovitch, Brian J Reid.   

Abstract

Neoplasms are thought to progress to cancer through genetic instability generating cellular diversity and clonal expansions driven by selection for mutations in cancer genes. Despite advances in the study of molecular biology of cancer genes, relatively little is known about evolutionary mechanisms that drive neoplastic progression. It is unknown, for example, which may be more predictive of future progression of a neoplasm: genetic homogenization of the neoplasm, possibly caused by a clonal expansion, or the accumulation of clonal diversity. Here, in a prospective study, we show that clonal diversity measures adapted from ecology and evolution can predict progression to adenocarcinoma in the premalignant condition known as Barrett's esophagus, even when controlling for established genetic risk factors, including lesions in TP53 (p53; ref. 6) and ploidy abnormalities. Progression to cancer through accumulation of clonal diversity, on which natural selection acts, may be a fundamental principle of neoplasia with important clinical implications.

Entities:  

Mesh:

Year:  2006        PMID: 16565718     DOI: 10.1038/ng1768

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  312 in total

Review 1.  Colorectal cancer molecular biology moves into clinical practice.

Authors:  Colin C Pritchard; William M Grady
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trial.

Authors:  Naser Davarzani; Lindsay C Hewitt; Matthew D Hale; Veerle Melotte; Matthew Nankivell; Gordon G A Hutchins; David Cunningham; William H Allum; Ruth E Langley; Shahab Jolani; Heike I Grabsch
Journal:  Dis Esophagus       Date:  2020-08-03       Impact factor: 3.429

3.  Tracing the tumor lineage.

Authors:  Nicholas E Navin; James Hicks
Journal:  Mol Oncol       Date:  2010-05-05       Impact factor: 6.603

Review 4.  Epigenetic biomarkers in esophageal cancer.

Authors:  Andrew M Kaz; William M Grady
Journal:  Cancer Lett       Date:  2012-03-07       Impact factor: 8.679

Review 5.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

6.  Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Authors:  Panteleimon Kountourakis; Jaffer A Ajani; Marta Davila; Jeffrey H Lee; Manoop S Bhutani; Julie G Izzo
Journal:  Gastrointest Cancer Res       Date:  2012-03

Review 7.  Somatic mosaicism: on the road to cancer.

Authors:  Luis C Fernández; Miguel Torres; Francisco X Real
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

Review 8.  An evolutionary perspective on field cancerization.

Authors:  Kit Curtius; Nicholas A Wright; Trevor A Graham
Journal:  Nat Rev Cancer       Date:  2017-12-08       Impact factor: 60.716

9.  Selection and adaptation during metastatic cancer progression.

Authors:  Christoph A Klein
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

10.  Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.

Authors:  Roman Reinartz; Shanshan Wang; Sied Kebir; Daniel J Silver; Anja Wieland; Tong Zheng; Marius Küpper; Laurèl Rauschenbach; Rolf Fimmers; Timothy M Shepherd; Daniel Trageser; Andreas Till; Niklas Schäfer; Martin Glas; Axel M Hillmer; Sven Cichon; Amy A Smith; Torsten Pietsch; Ying Liu; Brent A Reynolds; Anthony Yachnis; David W Pincus; Matthias Simon; Oliver Brüstle; Dennis A Steindler; Björn Scheffler
Journal:  Clin Cancer Res       Date:  2016-08-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.